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Abstract
Importance: Adults with Down syndrome (DS) are at high-risk of revealing Alzheimer’s
disease (AD) pathology, in part due to the triplication of chromosome 21 encoding the
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amyloid precursor protein. Adults with DS are uniformly affected by AD pathology by

4

their 30′s and have a 70% to 80% chance of clinical dementia by their 60′s. Our pre-
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vious studies have assessed longitudinal changes in amyloid beta (Aβ) accumulation in
DS.
Objective: The goal of the present study was to assess the presence of brain tau using
[18 F]AV-1451 positron emission tomography (PET) in DS and to assess the relationship
of brain tau pathology to Aβ using Pittsburgh Compound B (PiB)-PET.
Design: Cohort study
Setting: Multi-center study
Participants: Participants consisted of a sample of individuals with DS and sibling

Correspondence
Tudorascu Dana L, Department of
Psychiatry, 3501 Forbes Ave, Suite 830, Pittsburgh, PA 15213.
Email: dlt30@pitt.edu

controls recruited from the community; exclusion criteria included contraindications
for magnetic resonance imaging (MRI) and/or a medical or psychiatric condition that
impaired cognitive functioning.
Exposures: PET brain scans to assess Aβ ([11 C]PiB) and tau ([18 F]AV-1451) burden.

Funding information
National Institutes of Health, Grant/Award
Numbers: R01AG031110, U01AG051406

Main outcomes and measures: Multiple linear regression models (adjusted for chronological age, sex and performance site) were used to examine associations between
regional [18 F]AV-1451 standard uptake value ratio (SUVR) (based on regions associated with Braak stages 1-6) and global [11 C]PiB SUVR (as both a continuous and
dichotomous variable).
Results: A cohort of 156 participants (mean age = 39.05, SD(8.4)) were examined.
These results revealed a significant relationship between in vivo Aβ and tau pathology in DS. As a dichotomous variable, [18 F]AV-1451 retention was higher in each Braak
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region in PiB(+) participants. We also found, based on our statistical models, starting
with the Braak 3 region of interest (ROI), an acceleration of [18 F]AV-1451 SUVR deposition with [11 C]PiB SUVR increases.
KEYWORDS

Down syndrome, PET amyloid, TAU, Alzheimer’s disease

1

INTRODUCTION

a diagnosis of dementia, and for 8 participants the clinical consensus
was unable to determine a diagnosis.15 Based on our published PiB

Definitive diagnosis of Alzheimer’s disease (AD) relies on the demon-

thresholds,16 all of our participants were categorized as DS-PiB(−) or

stration of amyloid beta (Aβ) plaques and tau-containing neurofibril-

DS-PiB(+); briefly, any DS participant with PiB regional values exceed-

lary tangles at autopsy.1,2 More recently, the availability of positron

ing the threshold in at least one region of the six regions measured

emission tomography (PET) ligands for Aβ, such as [11 C]PiB3 and for

(anterior cingulate, frontal cortex, striatum, precuneus, lateral tempo-

tau, such as [18 F]AV-14514 have allowed in vivo examination of the

ral, and parietal cortices) is defined as DS-PiB(+). In addition, we also

relationship of cognition to AD pathophysiology. These studies have

included a sibling-control sample; all were classified as PiB(−).

demonstrated that tau pathology is more closely related to cogni-

Image Acquisition Imaging data were acquired at four sites: The

tive decline than Aβ2 and is associated with AD diagnosis,5 amyloid

University of Pittsburgh using a Siemens Prisma (magnetic resonance

positivity,6 and cognitive function.7

imaging; MRI) and a Siemens mCT Biograph (PET), the University of

Adults with Down syndrome (DS) are uniformly affected by AD-

Wisconsin-Madison using a General Electric Discovery MR750 (MRI)

related pathology, characterized by the presence of Aβ plaques by their

and a Siemens HR+ (PET), the University of Cambridge using a General

fourth decade (Wisniewski 1985; Hyman 1992; Lemere 1996), and

Electric SIGNA PET/MR (MRI and PET), and Banner Health using a Gen-

they demonstrate an increased prevalence of AD. From a large body of

eral Electric Discovery MR750 (MRI) and a General Electric Discovery

data, it is clear that overproduction of amyloid precursor protein (APP),

710 (PET). T1-weighted MR images were acquired for each subject for

in part due to the triplication of chromosome 21 encoding APP, is asso-

anatomical reference.

ciated with a high risk of AD in DS and the appearance of clinical AD at
an earlier age.8,9

PET tracers (15 mCi [11 C]PiB or 10 mCi [18 F]AV-1451, nominal)
were administered as bolus injections, over approximately 30 seconds,

Aβ PET studies in DS have identified a distinct pattern amyloid depo-

followed by a saline flush. Subjects were imaged over time ranges that

sition, beginning predictably in mid-life,10,11 which has been confirmed

included 50-70 minutes post-injection for the case of [11 C]PiB and 80-

in an autopsy study of DS.12,13 Tau PET studies in DS are relatively new,

100 minutes post-injection for the case of [18 F]AV-1451. For each sub-

with only one small study (n = 12) demonstrating increasing tau burden

ject, [18 F]AV-1451 scans were obtained in time proximity and, most

with age and amyloid positivity and a correlation between tau burden

frequently, on the same day following the [11 C]PiB scans.

impairment,14

mimicking the findings observed in late-

PET images were reconstructed into 45-minute time frames span-

onset AD using [18 F] AV-1451.5 Based on these data, we hypothesize

ning the range 50-70 minutes post-injection ([11 C]PiB) or 80-100

that higher regional Aβ measured by PiB-PET will be associated with

minutes post-injection ([18 F]AV-1451). Image reconstruction was per-

increased neurofibrillary tangles (NFTs) measured using AV-1451 PET.

formed using the manufacturer’s software and included correc-

This cross-sectional PET study aims to assess in DS the relationship

tions for scatter, deadtime, random coincidences, and radioactive

of global Aβ to regional neurofibrillary tangles (NFTs) characterized by

decay.

and cognitive

Braak staging.

2.2
2

Image processing

METHODS
The multiframe PET images were visually inspected for frame-to-frame

2.1

Study design and participants

motion. If necessary, motion correction was performed using a set
of stable frames (averaged) as a reference. Frames requiring correc-

All participants, n = 156 (135 DS and 21 controls), mean age = 39.05

tion were registered to the reference using PMOD. Single-frame PET

(SD = 8.4) underwent [11 C]PiB and [18 F]AV-1451 scans as well as clin-

images were formed by averaging over the 50-70 minute post-injection

ical and neuropsychological examination. All participants had a clini-

frames for PiB and over 80-100 minutes for AV-1451. Each subject’s

cal diagnosis based on consensus case conference. The consensus for

MRI was manually aligned to anterior-commissure/posterior commis-

our 135 DS participants was as follows: 108 were non-demented, non–

sure (ACPC) orientation. The single-frame PET images (PiB and AV-

mild cognitive impaired (MCI), 8 had a clinical diagnosis of MCI, 11 had

1451) were registered to this using the registration tool of PMOD
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(https://www.pmod.com/web/) via maximization of normalized mutual
information.

HIGHLIGHTS

Each subject’s T1 MRI was parcellated into regions of interest

∙ Question: The goal of this study was examine the relation-

(ROIs) using FreeSurfer v5.3. The standard FreeSurfer pipeline was

ship between amyloid and tau burden in Down syndrome

used for this procedure and modified to obtain a more finely detailed

(DS).
∙ Findings: In this multi-center population-based cohort

parcellation of the striatum than that produced by FreeSurfer with
the built-in Desikan-Killiany (DK) atlas. We incorporate the Clini-

study of DS we observed a significant relationship

cal Imaging Center (CIC) atlas,17 developed for dopamine imaging,

between in vivo amyloid beta (Aβ) and tau pathology in

into our analysis. The T1 MRI associated with CIC atlas was pro-

DS, similar to that seen in the typical aging population. We

cessed through FreeSurfer using the standard pipeline, providing a

also found, based on our statistical models, an acceleration

transformation that can be used to put the CIC atlas into internal

of [18F]AV-1451 SUVR deposition with [11C]PiB SUVR

FreeSurfer space. The net result of the procedure is that any scan

increases.
∙ Meaning: These data add to the existing body of literature

processed through FreeSurfer can be labeled with the CIC regions as
well as the FreeSurfer/DK regions. With this capability, subject scans

in DS to contribute to providing the necessary framework

were parcellated into FreeSurfer/DK regions, except that the stria-

to identify appropriate participants for clinical trials, track

tum was parcellated using CIC atlas regions. Specifically, the set of

efficacy of interventions, and track dementia progression

FreeSurfer DK regions (right and left) caudate, putamen, and pallidum

in the DS population.

were replaced by the set of CIC atlas regions (right and left) ventral
striatum, dorsal caudate, posterior caudate, anterior putamen, posterior putamen, and pallidum. All FreeSurfer results were inspected
and, if necessary, edited for proper anatomical alignment with the
MRI.

were normalized by dividing by cerebellar gray matter activity, deter-

For some subjects, however, the raw FreeSurfer (FS) results were

mined using a volume-weighted average of activity obtained using the

inadequate, even for editing. Based on work reported by Svarer et al.,18

FreeSurfer left and right cerebellar cortex ROIs. The result is a set of

some of these cases were salvaged using an approach in which scans

cerebellum gray matter normalized tissue ratios (standardized uptake

that were successfully parcellated by FreeSurfer were used as tem-

value ratios, SUVRs) for each ROI and tracer.

plates for the problematical scans. Briefly, a template ensemble was

A global region for amyloid status (positive or negative) was

assembled using 12 subjects (10 DS and 2 controls) from the Neurode-

composed from the region’s anterior cingulate, superior frontal,

generation in Aging Down Syndrome (NiAD) population with existing

orbitofrontal, insula, lateral temporal, parietal posterior cingulate, pre-

high-quality FS-based parcellations. All of the T1 template images were

cuneus, putamen, and striatum. The FreeSurfer and CIC atlas regions

skull stripped using the tissue segmentation function of SPM12 (Statis-

from which these are composed are listed in Supplemental Table S1.

tical Parametric Mapping, www.fil.ion.ucl.ac.uk/spm/software/spm12).

Parenthetically, because of the observation that the striatum of DS

Voxels with a combined probability of being white matter, gray mat-

subjects shows different patterns of amyloid deposition than in non-DS

ter, or cerebrospinal fluid of >0.0001 were classified as brain tissue

sporadic AD, a larger striatal region was used in DS studies than in non-

and retained in the image. Next, the T1 MR image from each subject to

DS. See Supplemental Table S1.1 and S1.2 for details. [11 C]PiB SUVRs

be processed was skull stripped using the procedure described for the

were determined for each of these super regions and ultimately for the

templates. For a given subject, each of the 12 template T1 MR images

global region via a volume-weighted average of the SUVRs of the com-

was warped to the skull-stripped subject image using the “Normalize”

ponent regions. Scans were defined to be amyloid positive, PiB (+), or

function of SPM8, and the existing FS parcellations were carried along

negative PiB (−), based on a global SUVR threshold of 1.36.

using the templates’ warping parameters. Using this method, for each

Six Braak super regions (Braak regions) corresponding to the six

FS region, 12 ROI images warped to the subject’s MRI were produced.

Braak stages19 were used for the quantitation of [18 F]AV-1451. The

A “probability image” was then generated by averaging the 12 individ-

Braak region SUVRs were determined from a volume-weighted aver-

ual template ROI images. The final probability-template ROI for the

age of SUVRs in sets of FreeSurfer regions described in Schöll et al.,20

region was constructed by selecting voxels with the highest probability

except that the striatum was not included in Braak region 5. The Braak

until a volume was achieved that was equal to the volume of that region

regions are exclusive in that, for example, Braak region 2 does not

averaged over the 12 warped templates. This process was repeated

include Braak region 1, and so on. As in the case of [11 C]PiB, [18 F]AV-

for every FS region resulting in a full set of FS-ROIs for each subject.

1451 SUVRs are normalized by cerebellar gray matter.

Final results were inspected and either accepted or rejected, but no
ROI editing was performed. Of 156 participants this method was utilized only on 20 participants, all in the DS group.

2.3

Statistical methods

For each subject, PET activity images (registered with the MRI)
were sampled using the ROIs determined as described above either

Descriptive statistics (means and standard deviations) are presented

using standard FS or our probability template method. Regional values

for age and for each Braak Region by DS-PiB (−), DS-PiB (+), and
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where:
RESEARCH IN CONTEXT

i) 𝛽0 represents the intercept (average Braak ROI SUVR value over

1. Systematic review: Tau positron emission tomography

the whole sample, for each ROI respectively);

(PET) studies in Down syndrome (DS) are relatively

Groupi is the dummy variable for group factor for subject i,

ii)

new, with only one small study (n = 12) demonstrat-

and 𝛽1 coefficient represents the difference in the mean of tau

ing increasing tau burden with age and amyloid posi-

SUVR between the DS-PiB (+) subjects compared to the controls,

tivity and a correlation between tau burden and cog-

whereas 𝛽2 represents the difference in the mean of Tau SUVR

nitive impairment; however, this study was preliminary

between the DS-PiB (−) subjects compared to the controls, taking

in nature. No studies have been undertaken to exam-

into the account the effect of site.

ine the relationship between amyloid and tau burden in

iii)

Sitei is the dummy variable for site factor for subject i, and the

DS. Our findings demonstrate a significant relationship

𝛽3 , 𝛽4 , and 𝛽5 coefficients for site represent the differences in the

between in vivo amyloid beta (Aβ) and tau pathology in

mean of tau SUVR between that specific site and the reference site

DS, similar to those seen in the typical aging popula-

when groups are fixed.

tion. As a dichotomous variable, [18F]AV-1451 retention
was higher in each Braak region in PiB(+) participants.

Controls are considered to be the reference category for groups

We also found, based on our statistical models, starting

and the site variable is included to account for variability due to data

with the Braak 3 region of interest (ROI) an acceleration

being collected at multiple sites (with UK as the reference site). The

of [18F]AV-1451 SUVR deposition with [11C]PiB SUVR

same model was rerun including age at scan and all the results are pre-

increases.

sented in Table 2 in the form of mean differences between the groups

2. Interpretation: These findings are among the first to

along with 95% confidence interval (CI), unadjusted (model 1) as well

report tau pathology using PET in DS and are, to our

as adjusted for age at scan (model 1+age). Based on the examination of

knowledge, the largest DS cohort using tau-PET. Our find-

scatter and LOESS (locally weighted scatterplot smoothing) plots of tau

ings suggest that tau pathology in DS does not differ from

SUVR as a function of Global PiB SUVR and guided by F-tests, we con-

that of late-onset AD, with tau pathology increasing in

sidered either linear or quadratic models for Braak ROIs 1 through 6.

regions associated with Braak regions in those with signif-

The F-tests were performed to test if the addition of the quadratic term

icant amyloid pathology. These data track with pathologi-

significantly added to explaining the variability in the model. Based on

cal studies in DS that have not identified clear differences

these evaluations, we used only a linear term for Braak ROIs 1 and 2

in neurofibrillary tau deposition from late-onset AD, but

(model 2) and added a quadratic term for Braak ROIs 3, 4, 5, and 6

unlike these neuropathological studies are not restricted

(model 3) with model terms described above.

to those with late-stage disease in all groups. In addition,
these data extend our previous findings, identifying a dis-

yi = 𝛽0 + 𝛽1 PiB_SUVRi + 𝛽2 Sitei1 + 𝛽3 Sitei2 + 𝛽4 Sitei3 + 𝜀i

tinct pattern of predominant striatal Aβ deposition that
distinguished the Aβ deposition seen in late-onset AD and

(2)

and

DS into tau pathology in DS.
3. Future directions: These data adding to the existing body

yi = 𝛽0 + 𝛽1 PiB_SUVRi + 𝛽2 PiB_SUVR2i + 𝛽3 Sitei1

of literature in DS contribute to providing the necessary

+𝛽4 Sitei2 + 𝛽5 Sitei3 + 𝜀i

framework to identify appropriate participants for clinical

(3)

trials, track efficacy of interventions, and track dementia
The regression coefficient estimates along with 95% CI unadjusted

progression in the DS population.

(model 2 and 3) and adjusted for age (model 2 and 3 including age) are
presented in Table 3. These estimates can be considered as effect sizes,
since they represent the amount of change in tau SUVR for each oneControls-PiB (−) in Table 1. Frequency percentages are shown for sex

unit change in PiB SUVR when site and age are fixed.
All of the above analyses were repeated for the DS-PiB(+) only,

and consensus diagnosis (Table 1).
To assess differences among DS-PiB(−), DS-PiB(+), and Controls-

and the results are presented in supplemental Table 2S and supple-

PiB(−), multiple linear regression models were used with dummy cod-

mental Figure 1S. None of our analyses were corrected for multiple

ing (0/1) for the groups and performance sites (group 1 is the DS-PiB

comparisons.

(+), group 2 is the DS-PiB (−), and Controls-PiB (−) are the reference
category) for each Braak ROI. The linear model used for each Braak ROI

3

is presented below:
yi = 𝛽0 + 𝛽1 Groupi1 + 𝛽2 Groupi2 + 𝛽3 Sitei1 + 𝛽4 Sitei2 + 𝛽5 Sitei3 + 𝜀i ,
(1)

RESULTS

In this cohort, we had 76 male and 80 female participants, with an
average age of 39.04 (SD = 9.00). The DS-PiB (+) participants had
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TA B L E 1

Descriptive statistics for groups for each Braak ROI

Variable

All N = 156

Controls-PiB
(−)n = 21

DS-PiB
(−)n = 73

DS-PiB
(+)n = 62

Consensus Dx 0 = no
MCI/no dementia

0 (108)

NA

0 (71)

0 (37)

1 = MCI

1(8)

1 (0)

1 (8)

2 = dementia

2 (11)

2 (0)

2 (11)

3 = unable to determine

3 (8)

3 (2)

3 (6)

Sex

M (76, 48%)

M (5, 24%)

M (36, 38%)

M (35, 56%)

Age at AV-1451 scan

39.04 (9.00)

39.00 (12.46)

33.61(4.80)

45.45 (7.15)

Braak Region 1

1.23 (0.22)

1.12 (0.07)

1.14 (0.10)

1.38 (0.27)

Braak Region 2

1.17 (0.21)

1.06 (0.13)

1.09 (0.10)

1.31 (0.26)

Braak Region 3

1.18 (0.25)

1.09(0.05)

1.10 (0.06)

1.30 (0.36)

Braak Region 4

1.14 (0.21)

1.08(0.07)

1.08 (0.07)

1.25 (0.29)

Braak Region 5

1.12 (0.25)

1.04 (0.06)

1.04 (0.06)

1.23 (0.36)

Braak Region 6

1.05 (0.21)

1.00 (0.08)

1.00 (0.06)

1.10 (0.30)

TA B L E 2

Estimated mean difference between groups for each Braak ROI
Estimated mean
differences and 95% CI

Region

Groups compared

Braak 1

DS-PiB (+) vs Controls-PiB (−)

0.23 (0.13, 0.32)

DS-PiB (−) vs Controls-PiB (−)

−0.01(−0.10, 0.08)

Braak 2

Braak 3

Braak 4

Braak 5

0.19 (0.10, 0.30)
0.01 (−0.08, 0.11)

DS-PiB (+) vs DS-PiB (−)

0.24 (0.18, 0.30)

0.18 (0.11, 0.26)

DS-PiB (+) vs Controls-PiB (−)

0.25 (0.15, 0.34)

0.20 (0.10, 0.29)

DS-PiB (−) vs Controls-PiB (−)

0.02 (−0.07, 0.11)

0.06 (−0.03, 0.15)

DS-PiB (+) vs DS-PiB (−)

0.22 (0.16, 0.29)

0.14 (0.06, 0.22)

DS-PiB (+) vs Controls-PiB (−)

0.20 (0.08, 0.32)

0.15 (0.03, 0.27)

DS-PiB (−) vs Controls-PiB (−)

−0.006 (−0.12, 0.11)

0.03 (−0.08, 0.15)

DS-PiB (+) vs DS-PiB (−)

0.21 (0.13, 0.29)

0.12 (0.02, 0.22)

DS-PiB (+) vs Controls-PiB (−)

0.17 (0.07,0.27)

0.12 (0.02, 0.22)

DS-PiB (−) vs Controls-PiB (−)

−0.002 (−0.10,0.09)

0.04 (−0.06, 0.13)

DS-PiB (+) vs DS-PiB (−)

0.17 (0.11, 0.24)

0.08 (0.003, 0.16)

DS-PiB (+) vs Controls-PiB (−)

0.18 (0.06, 0.30)

0.14 (0.02,0.27)

DS-PiB (−) vs Controls-PiB (−)

Braak 6

Estimated mean differences
and 95% CI (age adjusted)

−0.002 (−0.12,0.12)

0.03 (−0.09, 0.15)

DS-PiB (+) vs DS-PiB (−)

0.19 (0.12, 0.26)

0.12 (0.02, 0.22)

DS-PiB (+) vs Controls-PiB (−)

0.10 (−0.006, 0.20)

0.08 (−0.02, 0.19)

DS-PiB (−) vs Controls-PiB (−)
DS-PiB (+) vs DS-PiB (−)

−0.002 (−0.10,0.10)
0.10 (0.03, 0.17)

0.006 (−0.10, 0.11)
0.08 (−0.007, 0.17)

Note : Second column shows the estimated mean differences in AV-1451 SUVR between groups adjusted for site, and third column shows the differences
adjusted for site and age at scan.

an average age of 45.45 (SD = 7.15) years and the DS-PiB (−) had an

mean values are similar to the DS-PiB (−) mean values (see Table 1).

average age of 33.61 (SD = 4.80). The average Braak ROIs were higher

Using the multiple linear regression model, (equation 1), we found

for DS-PiB (+) than for the DS-PiB (−) or Control-PiB (−). These values

differences between DS-PiB (+) and DS-PiB (−) as well as between

were higher for lower Braak ROIs starting at 1.14 (SD = 0.10) for the

DS-PiB (+) and Control-PiB (−), and they are very close in magnitude.

DS-PiB (−) in Braak 1 ROI and decreasing to a value of 1.00 (0.06) in

These differences are presented in Table 2. It can be observed that the

Braak 6 ROI. Similarly, the DS-PiB (+) starts at an average value of

magnitude of the differences between DS-PiB (+) and DS-PiB (−) is

1.38 (SD = 0.27) in Braak 1 ROI SUV (see Table 1). The Control-PiB(−)

lower for higher Braak ROIs (ranging from 0.24, 95% CI [0.18, 0.30]
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Estimated coefficients from the regression models

Estimated PiB
SUVR coefficient
and 95% CI

Estimated
PiB2 SUVR
coefficient and
95% CI

4

DISCUSSION

The recent development of tau-PET ligands has provided the unique

Region

Intercept and
95% CI

Braak 1

0.57(0.43, 0.72)

0.52(0.44, 0.60)

NA

tifying a distinct pattern of predominant striatal Aβ deposition that dis-

Age adjusted 0.57(0.41, 0.63)

0.51(0.40,0.63)

NA

tinguished the Aβ deposition seen in late-onset AD and DS21 into tau

Braak 2

0.55(0.42, 0.69)

0.50(0.42, 0.57)

NA

pathology in DS. These finding are among the first to report tau pathol-

Age adjusted 0.53(0.38, 0.69)

0.47(0.37, 0.58)

NA

ogy using PET in DS and are, to our knowledge, the largest DS cohort

Braak 3

1.33(0.93, 1.75) −0.70(−1.22, −0.19) 0.43(0.27, 0.59)

Age adjusted 1.29(0.86, 1.72) −0.58(−1.22, 0.06)

0.40(0.22, 0.58)

1.11(0.75, 1.47) −0.33(−0.78, 0.13)

0.27(0.13, 0.41)

Age adjusted 1.09(0.71, 1.47) −0.29(−0.85, 0.28)

0.26(0.10, 0.42)

Braak 4

Braak 5

1.71(1.32, 2.11) −1.24(−1.74, −0.73) 0.59(0.43, 0.74)

Age adjusted 1.62(1.20, 2.04) −0.98(−1.60, 0.36)

opportunity to expand our knowledge of the natural history of AD
pathophysiology in DS. These data extend our previous findings, iden-

using tau PET.
These results demonstrate a significant relationship between in vivo
Aβ and tau pathology in DS, similar to those seen in the typical aging
population. The differences observed between amyloid-positive participants with DS and amyloid-negative participants with DS or amyloidnegative controls decreased in regions associated with the highest

0.52(0.35, 0.70)

Braak stages. This decreasing difference is likely a result of lower over-

2.11(1.73, 2.50) −1.73(−2.22, −1.24) 0.67(0.52, 0.82)

all tau pathology in Braak stages 5 and 6, given that the majority of

Age adjusted 1.97(1.57, 2.37) −1.35(−1.94, −0.76) 0.58(0.41, 0.75)

the participants in this study were non-demented and early in the time

Braak 6

course of AD pathophysiology. One limitation of the current study is
that the majority of the DS participants are classified as cognitively normal and were middle aged (39.04 years); expanding both the age and
in Braak 1 ROI, lower in Braak 4 ROI (0.17, 95% CI [0.11, 0.24]) and

cognitive function range of this cohort will be essential to understand-

much lower in Braak 6 ROI (0.10, 95% [0.03, 0.17]). We found that the

ing the full spectrum of AD.

differences between DS-PiB (+) and DS-PiB (−) in Braak 2 and 3 ROIs

Although we observed decreasing differences in overall tau pathol-

were very close to each other. All these differences became lower

ogy in regions associated with higher Braak stages, our quadratic mod-

when the models were adjusted for age at scan (Table 2).

els suggest an acceleration of tau pathology in regions associated with

The associations between tau SUVR and PiB SUVR were in the range

higher Braak stages as amyloid pathology increases. Indeed in Braak

of moderate effect sizes for most of the coefficients. A linear associa-

ROIs 5 and 6, the quadratic coefficient indicates a steeper increase

tion was found between tau SUVR in Braak 1 ROI, β = 0.52 (0.44, 0.60)

(0.59 in Braak 5 and 0.67 in Braak 6, Figure 1) associated with accumu-

and Braak 2, β = 0.50 (0.42, 0.57), suggesting that for each one unit

lating Aβ. Our findings suggest that tau pathology in DS does not dif-

increase in Global PiB SUVR there is a 0.52 increase in tau SUVR for

fer from that in late-onset AD, with tau pathology increasing in regions

Braak 1 and a 0.50 increase in tau SUVR for Braak 2. Similar effects

associated with Braak regions in those with significant amyloid pathol-

were determined when models were additionally adjusted for age.

ogy. These data track with pathological studies in DS that have not

These values were determined from the coefficients of PiB SUVR from

identified clear differences in neurofibrillary tau deposition from late-

model 2 and are presented in Table 3.

onset AD, but these are restricted to patients with late-stage disease

Starting with the Braak 3 ROI, we have found an acceleration of tau

in all groups.22–24 This model also supports the hypothesis that amy-

SUVR deposition with PiB SUVR increase. This acceleration is deter-

loid pathology is an initiating event leading to the spread of tau from

mined by the coefficient of the quadratic PiB SUVR term. Using model

the medial temporal lobes to neocortex, increasing the rate of accu-

3, this coefficient gives information with respect to the direction and

mulation as tau levels increase.25 However, additional longitudinal data

the steepness of the relationship between these variables. All of the

from DS participants with AD will be required to determine if our mod-

associations that were found were convex (a positive curvature), with

els do in fact represent the true AD pathophysiology in DS and match

lower coefficients for Braak 3 ROI (0.43, 95% CI [0.27, 0.59]) and Braak

those identified in pathological studies.

4 ROI (0.27, 95% CI [0.13, 0.41]) and higher quadratic coefficients in

Two technical limitations in the present study are the use of the

Braak 5 ROI (0.59, 95% CI [0.43, 0.74]) and Braak 6 ROI (0.67, 95% CI

cerebellum as a reference region for [11 C]PiB and the use of the 80-

[0.52, 0.82]). Mathematically, this indicates that, as PiB SUVR increases,

100 analysis window for [18 F]AV-1451 . We acknowledge the find-

the tau amyloid changes by 𝛽1 + 2𝛽2 PiB_SUVR (the derivative of the

ings reported in the literature of improved sensitivity with PiB using

quadratic model 3 with respect to the Global PiB SUVR). For example,

the white matter reference region (Brendel et al., 2015; Chen et al.,

for a value of Global-PIB SUVR equal to 1.5, the estimated TAU SUVR in

2015; Schwarz et al., 2017), particularly related to addressing the

Braak 3 ROI will be 1.8 (-0.70+2*0.43*1.5 = 1.8, Table 3). For a value of

shortcomings of technical variability introduced by differences in scan-

Global-PiB SUVR equal to 2.5, the estimated tau SUVR in Braak 6 will

ner slice sensitivity and noise. However, we feel strongly that cere-

be 1.62 (-1.73+2*0.67*1.25 = 1.62).

bellar gray matter reference region provides a more accurate physi-

The plots showing the linear and the quadratic associations are presented in Figure 1.

ological representation of amyloid and tau burden. Considering that
the SUVR metric serves as a proxy for the distribution volume ratio

7 of 8

TUDORASCU ET AL .

2.0

2.2

1.5

2.0

Braak 3 SUVR

1.6
1.4
1.2

Braak 2 SUVR

2.5

1.8

2.0
1.8
1.6
1.4
Controls_neg DS_neg

1.0

0.8

1.0

1.0

1.2

Controls_neg DS_neg

DS_pos

Controls_neg DS_neg

DS_pos

Groups

Groups

Braak ROI 4

Braak ROI 5

Braak ROI 6

2.0
1.5

Braak 5 SUVR

2.0
1.5

Braak 5 SUVR

1.8
1.6
1.4

1.0

1.0

1.0

1.2

Braak 4 SUVR

2.0

2.2

2.5

Groups

DS_pos

2.5

Braak 1 SUVR

Braak ROI 3

Braak ROI 2

Braak ROI 1

Controls_neg DS_neg

DS_pos

Controls_neg DS_neg

Groups

DS_pos

Groups

Controls_neg DS_neg

DS_pos

Groups

F I G U R E 1 Models for AV-1451 with Global-PiB SUVR. The plots are showing the linear and quadratic model fit lines for each Braak region
(shown on y-axes) and Global-PiB SUVR (shown on x-axes)
(DVR) or binding potential (BPND ), the non-displaceable distribution

Furthermore, these data add to our understanding of AD pathology in

volume (V_ND = K1/k2’) should be close to equal in these gray mat-

DS, expanding from the large body of literature related to amyloid PET

ter tissue regions (and thus cancel out in the ratio), and that the over-

by exploring tau PET and are an important first step in understanding

all findings would be expected to be compatible. In addition, it has

the natural history of amyloid and tau in the transition to dementia

been suggested that the analyses of [18 F]AV-1451 using the 80-100

in DS. Furthermore, these biomarker data will provide the necessary

minute window may underestimate the SUVR values, particularly in

framework to identify appropriate participants for clinical trials,

the high binding range; however, in the same study it was suggested

track efficacy of interventions, and track dementia progression in this

that the 80-100 minute was best for studying the full range of tau

population.

pathology.26
As we move toward an era of dementia prevention trials in DS, an
understanding of the natural history of AD pathophysiology in DS is
critical.27

5

CONCLUSIONS AND RELEVANCE

These data do not yet provide information about the role of

tau pathology in the transition to clinical dementia; however, ongoing

These data demonstrate that similar to late-onset AD, in vivo Aβ and

collection of longitudinal cognitive and imaging data within this cohort

tau pathology are associated in DS. In addition, these data suggest a

will provide data to answer this important question in the further.

higher tau pathology in regions associated with higher Braak stages
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as amyloid pathology increases. These finding are among the first to
report tau pathology using PET in DS and are, to our knowledge, the
largest DS cohort using tau PET. The data also contribute to providing
the necessary framework to identify appropriate participants for clinical trials, track efficacy of interventions, and track dementia progression in the DS population.
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